NCT04445701: Phase 1/2: Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dex RRMM

• NCT04445701: Phase 1/2: Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma

Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma

Open-label, dose escalation study to evaluate the safety, tolerability, pharmacokinetics (PK)/pharmacodynamics and initial efficacy of AO-176 as monotherapy and in combination with dexamethasone and bortezomib in adults with relapsed/refractory multiple myeloma (MM).

Sponsor

Arch Oncology

---

ClinicalTrials.gov Identifier: NCT04445701

Official Title: A Phase 1/2, Dose Escalation Safety and Tolerability Study of AO-176 as Monotherapy and in Combination With Bortezomib and Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma

First Posted : June 24, 2020

Click here to see details on ClinicalTrials.gov

---

Drug: AO-176 Drug: AO-176 + Dex

Drug: AO-176 + Dex + Bort

AO-176

Anti-CD47 Monoclonal Antibody AO-176 (Code C159600)

Anti-CD47 Monoclonal Antibody AO-176

AO 176

AO-176

AO176

---

Locations

United States, Arizona

United States, Florida

United States, Georgia

United States, Massachusetts

United States, Minnesota

United States, Washington

United States, Wisconsin